[G22-39] Axicabtagene ciloleucel (DLBCL and HGBL) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V
Last updated 12.01.2023
Project no.:
G22-39
Commission:
Commission awarded on 15.11.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Withdrawn commission
Department/Division:
Health Economics
Topic:
Cancer
Note:
In accordance with §35a (1) Sentence 11 Social Code Book (SGB) V, the added medical benefit of orphan drugs is deemed as proven by the fact that they have been approved. On behalf of the Federal Joint Committee (G-BA), IQWiG therefore solely assesses the information on patient numbers and costs in the pharmaceutical company's dossier.
| Project no. | Title | Status |
|---|---|---|
| G22-19 | Axicabtagene ciloleucel (diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V (expiry of the decision) | Commission completed |
| G18-18 | Axicabtagene ciloleucel (B-cell lymphoma DLBCL) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V | Commission completed |
| G18-19 | Axicabtagene ciloleucel (B-cell lymphoma PMBCL) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V | Commission completed |
| G22-40 | Axicabtagene ciloleucel (follicular lymphoma) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V | Withdrawn commission |